skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All


Show More


Show More


Show More

Show More

29 Total results for product and free and sample content found

In Vivo, Pink Sheet

Manufacturing and Distribution: Challenges and Opportunities

13 May 2021

Manufacturing and Distribution eBook

The COVID-19 pandemic has brought about significant manufacturing and distribution challenges and opportunities for Pharma. Seize new opportunities and avoid risk with the strategic commercial and regulatory intelligence you need to stay competitive by subscribing to Pink Sheet and In Vivo.

Topic Strategy

In Vivo

ESG In 2020: Not A Tick-Box Exercise But A Strategic Opportunity

By William Looney 27 Nov 2020


The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.

Topic Financing Strategy

In Vivo

World Vision 360° Pack

21 Jul 2020


Get a global perspective on the current state of the pharma and medtech industries with In Vivo’s World Vision 360° article pack. Access your free pack for essential insights into research and development, innovations, trends and strategies for markets around the world.

Topic Research & Development Strategy

Generics Bulletin

Lupin Offloads Kyowa For $525m But Not Exiting Japan

By Vibha Ravi 13 Nov 2019


Lupin plans to invest in acquisitions and organic growth in the US and India after selling Japanese subsidiary Kyowa Pharma for an enterprise value of around $525m to Japan private equity group Unison Capital. But the Indian firm stresses it is not exiting Japan and will continue to look for marketing partnerships.

Topic Deals Strategy

Generics Bulletin

Teva Debuts US Rituximab At A 10% Discount

By David Wallace 08 Nov 2019


Teva and Celltrion have launched the first biosimilar rituximab in the US, introducing Truxima at a 10% discount to Roche’s Rituxan.

Topic Biosimilars Strategy


Introducing Meddevicetracker's Market Analysis Tool

02 Aug 2019

Introducing Meddevicetracker's Market Analysis Tool

Find and manipulate the essential medical devices and diagnostics market intelligence you rely on from Meddevicetracker’s Market Analysis Reports with Meddevicetracker’s new interactive Market Analysis tool. 

Topic Strategy Business Strategies Company Analysis

HBW Insight

PAGB Looks To The Future As It Celebrates 100-Year Anniversary

By Tom Gallen 04 Jul 2019

PAGB Looks To The Future As It Celebrates 100-Year Anniversary

Maximizing opportunities from digital technology, addressing environmental concerns and responding to the challenges of Brexit are among the Proprietary Association of Great Britain's top priorities as it enters its second century. The association invited guests from around the world to celebrate its centenary at a gala dinner in London on 17 June.

Topic Brexit Digital Health Strategy

Pink Sheet

Will US Government Pursue Fewer False Claims Act Cases In 2019

By Brenda Sandburg 03 Jul 2019

Will US Government Pursue Fewer False Claims Act Cases In 2019

Fallout from Supreme Court's Escobar decision and Department of Justice memos could impact types of healthcare fraud complaints in which the government intervenes.

Topic Approvals Strategy


Allergan's Big Deal: A Buyout, Not A Split, Appeases Wary Investors

By Mandy Jackson 26 Jun 2019

Allergan's Big Deal: A Buyout, Not A Split, Appeases Wary Investors

Allergan was expected to announce soon that it would follow its shareholders' advice and split the company in two, but it's being acquired by AbbVie for $63bn instead, finally giving investors a big boost in their Allergan holdings after years of decline.

Topic Business Strategies Strategy

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: